Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

OBJECTIVES: This phase II trial evaluated the efficacy and safety of an interleukin (IL) 6 monoclonal antibody for systemic lupus erythematosus (SLE). METHODS: Patients with active disease were randomised to placebo or PF-04236921 10 mg, 50 mg or 200 mg, subcutaneously, every 8 weeks with stable bac...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallace, Daniel J, Strand, Vibeke, Merrill, Joan T, Popa, Serghei, Spindler, Alberto J, Eimon, Alicia, Petri, Michelle, Smolen, Josef S, Wajdula, Joseph, Christensen, Jared, Li, Cheryl, Diehl, Annette, Vincent, Michael S, Beebe, Jean, Healey, Paul, Sridharan, Sudhakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446001/
https://www.ncbi.nlm.nih.gov/pubmed/27672124
http://dx.doi.org/10.1136/annrheumdis-2016-209668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446001/
https://www.ncbi.nlm.nih.gov/pubmed/27672124
http://dx.doi.org/10.1136/annrheumdis-2016-209668

Ejemplares similares